A Costimulatory CAR Improves TCR-based Cancer Immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Immunology Research"
DOI: 10.1158/2326-6066.cir-21-0307
Abstract: This proof-of-concept study demonstrates that TCR-based therapies can be improved with engineered T cells expressing a costimulatory chimeric antigen receptor (CoCAR). CoCAR+ T cells are able to kill TCR targets, while sparing normal cells expressing… read more here.
Keywords: improves tcr; costimulatory car; car improves; costimulatory ... See more keywords